pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2015-25-5-622-627pulmo-630Research ArticleОБЗОРЫREVIEWКомбинация вилантерол / флутиказона фуроат (Релвар Эллипта®) при бронхиальной астме: обзор клинических исследованийFluticasione furoate / vilanterol combination (Relvar Ellipta®) in bronchial asthma: a review of clinical trialsЧикинаС. Ю.ChikinaS. Yu.

к. м. н., старший научный сотрудник лаборатории функциональных и ультразвуковых методов исследования ФГБУ «НИИ пульмонологии» ФМБА; тел.: (495) 9677744

PhD, Senior Researcher at Laboratory of Functional and Ultrasound Investigations; Federal Institution «Pulmonology Research Institute», Federal Medical and Biological Agency of Russia; tel.: (495) 9677744

svch@list.ruФГБУ «НИИ пульмонологии» ФМБА: 105077, Москва, ул. 11&я Парковая, 32, корп. 4РоссияFederal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia: 32, build. 4, 11th Parkovaya str., Moscow, 105077, RussiaRussian Federation201513012016255622627Copyright © Чикина С.Ю., 20162016Чикина С.Ю.Chikina S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/630

Представлен обзор литературы о клинической эффективности и безопасности новой комбинации ингаляционного глюкокортикостероида флутиказона фуроата (ФФ) и длительно действующего β2агониста вилантерола в лечении бронхиальной астмы (БА). При комбинированной терапии вилантеролом / ФФ эффективно снижаются риск и частота тяжелых обострений БА, улучшаются легочная функция, качество жизни больных и степень контроля над БА, уменьшаются частота симптомов и потребность в быстродействующих бронхолитических препаратах (БП) для купирования симптомов, повышается число бессимптомных дней и дней без потребности в быстродействующих БП при применении 1 раз в сутки. Одинаковая клиническая эффективность и безопасность комбинации вилантерол / ФФ при утреннем и вечернем назначении позволяет выбрать наиболее удобный для пациента режим терапии, что потенциально может улучшить приверженность лечению. Переносимость комбинированной терапии у пациентов с БА вилантеролом / ФФ достоверно не отличается от плацебо. ФФ в комбинации с вилантеролом выпускается в новом, простом и удобном в использовании ингаляционном устройстве Эллипта®.

This review has summarized clinical trials data on efficacy and safety of new combination of inhaled steroid fluticasione furoate (FF) and longacting beta2agonist vilanterol in patients with bronchial asthma. Treatment with this combination could effectively reduce a risk and frequency of severe asthma exacerbations, improve lung function, quality of life and control of asthma, improve asthma symptoms and need in relief medications, increase number of days without asthma symptoms and without use of asneeded bronchodilators. This combination was equally effective being administered both in the morning and in the evening that, in turn, allowed the most convenient treatment regimen for the patient and could additionally improve control of the disease. Tolerability of the FF / vilanterol combination is similar to that of placebo. The FF / vilanterol combination is delivered via a new inhalation device Ellipta® which is ease and convenient to use.

бронхиальная астмаингаляционные глюкокортикостероидыдлительно действующие β2агонистыфлутиказона фуроатвилантеролЭллипта®bronchial asthmainhaled steroidslongacting beta2agonistsvilanterolfluticasione furoateEllipta®.ReferencesGlobal Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2015.Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2015.Cazzola M., Matera M.G. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 2009; 34: 757–769.Cazzola M., Matera M.G. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 2009; 34: 757–769.Biggadike K., Bledsoe R.K., Hassell A.M. et al. Xray crystal structure of the novel enhancedaffinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptorligand binding domain. J. Med. Chem. 2008; 51 (12): 3349–3352.Biggadike K., Bledsoe R.K., Hassell A.M. et al. Xray crystal structure of the novel enhancedaffinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptorligand binding domain. J. Med. Chem. 2008; 51 (12): 3349–3352.Allen A., Schenkenberger I., Trivedi R. et al. Inhaled fluticasone furoate / vilanterol does not affect hypothalamic pituitaryadrenal axis function in adolescent and adult asthma: randomised, doubleblind, placebocontrolled study. Clin. Respir. J. 2013; 7 (4): 397–406.Allen A., Schenkenberger I., Trivedi R. et al. Inhaled fluticasone furoate / vilanterol does not affect hypothalamic pituitaryadrenal axis function in adolescent and adult asthma: randomised, doubleblind, placebocontrolled study. Clin. Respir. J. 2013; 7 (4): 397–406.Oliver A., Bjermer L., Quinn D. et al. Modulation of aller geninduced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013; 68 (9):1136–1142.Oliver A., Bjermer L., Quinn D. et al. Modulation of aller geninduced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013; 68 (9):1136–1142.Bleecker E.R., Lötvall J., O'Byrne P.M. et al. Fluticasone furoatevilanterol 100–25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J. Allergy Clin. Immunol. Pract. 2014; 2 (5): 553–561.Bleecker E.R., Lötvall J., O'Byrne P.M. et al. Fluticasone furoatevilanterol 100–25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J. Allergy Clin. Immunol. Pract. 2014; 2 (5): 553–561.Bateman E.D., O'Byrne P.M., Busse W.W. et al. Oncedaily fluticasone furoate (FF) / vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014; 69 (4): 312–319.Bateman E.D., O'Byrne P.M., Busse W.W. et al. Oncedaily fluticasone furoate (FF) / vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014; 69 (4): 312–319.O'Byrne P.M., Bleecker E.R., Bateman E.D. et al. Once daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur. Respir. J. 2014; 43 (3): 773–782.O'Byrne P.M., Bleecker E.R., Bateman E.D. et al. Once daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur. Respir. J. 2014; 43 (3): 773–782.Kempsford R.D., Oliver A., Bal J. et al. The efficacy of oncedaily fluticasone furoate / vilanterol in asthma is comparable with morning or evening dosing. Respir. Med. 2013; 107 (12): 1873–1880.Kempsford R.D., Oliver A., Bal J. et al. The efficacy of oncedaily fluticasone furoate / vilanterol in asthma is comparable with morning or evening dosing. Respir. Med. 2013; 107 (12): 1873–1880.Woodcock A., Bateman E.D., Busse W.W. et al. Efficacy in asthma of oncedaily treatment with fluticasone furoate: a randomized, placebocontrolled trial. Respir. Res. 2011; 12: 132.Woodcock A., Bateman E.D., Busse W.W. et al. Efficacy in asthma of oncedaily treatment with fluticasone furoate: a randomized, placebocontrolled trial. Respir. Res. 2011; 12: 132.Busse W.W., Bleecker E.R., Bateman E.D. et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8week, randomised, placebocontrolled trial. Thorax. 2012; 67 (1): 35–41.Busse W.W., Bleecker E.R., Bateman E.D. et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8week, randomised, placebocontrolled trial. Thorax. 2012; 67 (1): 35–41.Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.Svedsater H., Jacques L., Goldfrad C., Bleecker E.R. Ease of use of the Ellipta dry powder inhaler: data from three randomized controlled trials in patients with asthma. Primary Care Respir. Med. 2014; 24: 14019. DOI: 10.1038/npjpcrm. 2014.19.Svedsater H., Jacques L., Goldfrad C., Bleecker E.R. Ease of use of the Ellipta dry powder inhaler: data from three randomized controlled trials in patients with asthma. Primary Care Respir. Med. 2014; 24: 14019. DOI: 10.1038/npjpcrm. 2014.19.Sharma R., Komase Y., Akimoto A., Kobayashi A. Operability of the ElliptaTM dry powder inhaler: a comparative evaluation of handling technique in inhalation therapynaїve subjects. Am. J. Respir. Crit. Care Med. 2014; 189: A5693.Sharma R., Komase Y., Akimoto A., Kobayashi A. Operability of the ElliptaTM dry powder inhaler: a comparative evaluation of handling technique in inhalation therapynaїve subjects. Am. J. Respir. Crit. Care Med. 2014; 189: A5693.

The authors declare that there are no conflicts of interest present.